These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36870274)

  • 1. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.
    Silveira SQ; da Silva LM; de Campos Vieira Abib A; de Moura DTH; de Moura EGH; Santos LB; Ho AM; Nersessian RSF; Lima FLM; Silva MV; Mizubuti GB
    J Clin Anesth; 2023 Aug; 87():111091. PubMed ID: 36870274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia.
    Sen S; Potnuru PP; Hernandez N; Goehl C; Praestholm C; Sridhar S; Nwokolo OO
    JAMA Surg; 2024 Jun; 159(6):660-667. PubMed ID: 38446466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying.
    Fujino E; Cobb KW; Schoenherr J; Gouker L; Lund E
    Cureus; 2023 Jul; 15(7):e42153. PubMed ID: 37602101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.
    Gulak MA; Murphy P
    Can J Anaesth; 2023 Aug; 70(8):1397-1400. PubMed ID: 37280458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
    Klein SR; Hobai IA
    Can J Anaesth; 2023 Aug; 70(8):1394-1396. PubMed ID: 36977934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
    Wu F; Smith MR; Mueller AL; Klapman SA; Everett LL; Houle T; Kuo B; Hobai IA
    Can J Anaesth; 2024 Mar; ():. PubMed ID: 38485835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence.
    Queiroz VNF; Falsarella PM; Chaves RCF; Takaoka F; Socolowski LR; Garcia RG
    Einstein (Sao Paulo); 2023; 21():eRC0628. PubMed ID: 38126547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Predictors of Adverse Events during Procedural Sedation Anesthesia-Outside the Operating Room for Esophagogastroduodenoscopy and Colonoscopy in Children: Age Is an Independent Predictor of Outcomes.
    Biber JL; Allareddy V; Allareddy V; Gallagher SM; Couloures KG; Speicher DG; Cravero JP; Stormorken AG
    Pediatr Crit Care Med; 2015 Oct; 16(8):e251-9. PubMed ID: 26218257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li A; Su X; Hu S; Wang Y
    Diabetes Res Clin Pract; 2023 Apr; 198():110605. PubMed ID: 36871874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
    Dahl K; Brooks A; Almazedi F; Hoff ST; Boschini C; Baekdal TA
    Diabetes Obes Metab; 2021 Jul; 23(7):1594-1603. PubMed ID: 33710717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of propofol sedation for elective nonintubated esophagogastroduodenoscopy in pediatric patients.
    Rajasekaran S; Hackbarth RM; Davis AT; Kopec JS; Cloney DL; Fitzgerald RK; Hassan NE; Ndika AN; Cornelius K; McCullough A; Sanfilippo D
    Pediatr Crit Care Med; 2014 Jul; 15(6):e261-9. PubMed ID: 24849145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acupuncture to improve tolerance of diagnostic esophagogastroduodenoscopy in patients without systemic sedation: results of a single-center, double-blinded, randomized controlled trial (DRKS00000164).
    Schaible A; Schwan K; Bruckner T; Plaschke K; Büchler MW; Weigand M; Sauer P; Bopp C; Knebel P
    Trials; 2016 Jul; 17(1):350. PubMed ID: 27455961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
    JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
    N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk residual gastric content in fasted patients undergoing gastrointestinal endoscopy: a prospective cohort study of prevalence and predictors.
    Phillips S; Liang SS; Formaz-Preston A; Stewart PA
    Anaesth Intensive Care; 2015 Nov; 43(6):728-33. PubMed ID: 26603797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.